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Abstract
Diabetes mellitus type II (DM II) or adult onset diabetes is due to the inefficient use of insulin,
which affects various organs and tissues. Patients with DM II are at risk of suffering non-alcoholic
fatty liver disease (NAFLD) that can later develop into more life threating forms such as hep-
atomegaly, cirrhosis or liver cancer. Following the logic of the non-inferiority trial test, we aim
to establish a more accurate anatomical measure of the right liver lobe (RLL) to facilitate close
monitoring of liver size with ultrasound (US). We hypothesize that US is not unacceptably worse
than computed tomography (CT) or magnetic resonance imaging (MRI) to accurately and reliably
measure the size of the RLL when the measure is taken in the midaxillary line and craniocaudal
plane (MAL-CC). Therefore, the objective of this study is to conduct a non-inferiority trial to test
our novel MAL-CC measure.
To meet this aim, US measure of the RLL was taken from DM II (n=7) and non-DM II (n=5)
patients, whom were recruited from 2 endocrinology clinics at SoM-UPR. Preliminary data shows
that MAL-CC measure of the RLL from non-DM II patients is 13.99 + 2.53 cm whereas the same
measurement among DM II patients is 15.25 + 3.25 cm (Mann-Whitney U test, p= 0.42). It is
concluded that there is a non-significant trend for large RLL sizes among DM II patients. Future
work aims to increase sample size and to validate our novel measurement with MRI.
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ABSTRACT   
Diabetes mellitus type II (DM II) or adult onset diabetes is due to the inefficient use of 
insulin, which affects various organs and tissues. Patients with DM II are at risk of suffering non-
alcoholic fatty liver disease (NAFLD) that can later develop into more life threating forms such as 
hepatomegaly, cirrhosis or liver cancer. Following the logic of the non-inferiority trial test, we aim 
to establish a more accurate anatomical measure of the right liver lobe (RLL) to facilitate close 
monitoring of liver size with ultrasound (US). We hypothesize that US is not unacceptably worse 
than computed tomography (CT) or magnetic resonance imaging (MRI) to accurately and reliably 
measure the size of the RLL when the measure is taken in the midaxillary line and craniocaudal 
plane (MAL-CC). Therefore, the objective of this study is to conduct a non-inferiority trial to test 
our novel MAL-CC measure. 
To meet this aim, US measure of the RLL was taken from DM II (n=7) and non-DM II 
(n=5) patients, whom were recruited from 2 endocrinology clinics at SoM-UPR. Preliminary data 
shows that MAL-CC measure of the RLL from non-DM II patients is 13.99 + 2.53 cm whereas 
the same measurement among DM II patients is 15.25 + 3.25 cm (Mann-Whitney U test, p= 0.42). 
It is concluded that there is a non-significant trend for large RLL sizes among DM II patients. 
Future work aims to increase sample size and to validate our novel measurement with MRI. 
 
Keywords: diabetes mellitus type II (DM II), nonalcoholic fatty liver disease (NAFLD),  
ultrasound, liver, right liver lobe (RLL) 
 
ACKNOWLEDGEMENTS 
The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive 
and Kidney Diseases of the National Institutes of Health, Grant number: 1R25DK098067-01. 
